A multi-center ACTION registry study found that while VAD removal following heart recovery is rare in children (about 3%), nearly three-quarters of those who underwent explantation remained alive without needing a transplant or new device at two-year follow-up.
Right ventricular failure (RVF) after left ventricular assist device (LVAD) implantation is a major cause of morbidity and mortality. This review offers pediatric-focused guidance on perioperative RV management, emphasizing pathophysiology, hemodynamics, and targeted interventions to optimize outcomes.
ACTION and the Academic Research Consortium (ARC) aimed to harmonize definitions of pediatric and CHD AEs for use in clinical trials, registries, and regulatory evaluation.
Abstract We sought to develop a contemporary risk assessment tool for use in pediatric ventricular assist device (VAD) candidates to estimate risk for mortality on the device using readily available
Taking ACTION: A Prognostic Tool for Pediatric Ventricular Assist Device Mortality Read More »
VAD support for patients with Fontan circulatory failure is increasing, yet outcomes are largely unknown. Published on Nov. 21, 2021, Systemic ventricular assist device support of the Fontan circulation yields
Despite the fact that VADs are now regarded as an important treatment option in pediatric heart failure, most hospitals perform less than 10 VAD surgeries in children a year. “ISHLT
ISHLT Consensus Statement for the Selection and Management of Pediatric and CHD on VAD Read More »
The Jarvik 2015 VAD, the first and currently only continuous-flow VAD specifically designed for small children, is being assessed in the Pump for Kids, Infants, and Neonates (PumpKIN) trial. Inclusion
“Compassionate” Cases of the Jarvik 2015 VAD Read More »
